All volunteers vaccinated by Siberia’s Vector Research Center’s EpiVacCorona coronavirus formula have developed antibodies. The vaccine has completed its first two phases of testing, involving just 100 people.
While a vaccine needs thousands of people to be tested before its quality is proven, the latest news is an optimistic sign for the future.
Continue reading https://on.rt.com/avg8